Clinical Trials Logo

Clinical Trial Summary

This is an open label, multicenter, phase Ib study evaluating IBI310 (anti-CTLA-4) in combination with Sintilimab in patients with advanced, recurrent or metastatic non-small-cell lung cancer(NSCLC)

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05118334
Study type Interventional
Source Innovent Biologics (Suzhou) Co. Ltd.
Contact Xiuzhi Yu
Phone 0512-69566088
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date November 12, 2021
Completion date June 30, 2023